Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML)
have revealed a striking heterogeneity with regard to the presence of acquired gene …

Retinoids (ie, vitamin A, all-trans retinoic acid, and related signaling molecules) induce the
differentiation of various types of stem cells. Nuclear retinoic acid receptors mediate most but …

As more clinically-relevant genomic features of myeloid malignancies are revealed, it has
become clear that targeted clinical genetic testing is inadequate for risk stratification. Here …

Purpose To study the incidence and prognostic impact of mutations in DNA
methyltransferase 3A (DNMT3A) in patients with acute myeloid leukemia. Patients and …

Blocked cellular differentiation is a central pathologic feature of the myeloid malignancies,
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Treatment regimens …

The bone marrow (BM) microenvironment regulates acute myeloid leukemia (AML) initiation,
proliferation, and chemotherapy resistance. Following cancer cell death, a growing body of …

There is experimental and observational evidence that the cells of the leukemic clone in
acute myeloid leukemia (AML) have different phenotypes even though they share the same …

Mutations in the cohesin complex are novel, genetic lesions in acute myeloid leukemia
(AML) that are not well characterized. In this study, we analyzed the frequency, clinical, and …

Acute myelogenous leukemia (AML) is a heterogeneous disorder characterized by clonal
proliferation of stem cell-like blasts in bone marrow (BM); however, their unique cellular …

The nucleoside analog cytarabine (Ara-C) is an essential component of primary and salvage
chemotherapy regimens for acute myeloid leukemia (AML). After cellular uptake, Ara-C is …